ACC-001: A Case Study of a Promising Alzheimer’s Vaccine Therapy
One of the most promising areas of Alzheimer’s disease research involves vaccine-based therapies which stimulate the body to produce antibodies to amyloid-beta protein and remove it from the brain. And despite setbacks in previous clinical trials, scientists are currently working on second-generation vaccines that seem to reverse the cognitive deficits of Alzheimer’s disease without the side effects of the first-generation therapies.
In this podcast, we speak with Dr. Gene Kinney of Janssen Alzheimer Immunotherapy and Dr. Michael Hagen of Pfizer Pharmaceuticals. Dr. Kinney and Dr. Hagan are involved with the research and development of ACC-001, one of the most advanced second-generation vaccine-based therapies under development.
Be sure to listen in as we discuss the potential of this new therapy and what it might mean for the future of Alzheimer’s disease treatment.